Patents by Inventor David R. EDGELL

David R. EDGELL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12312615
    Abstract: Provided herein are modified Staphylococcus aureus Cas9 nucleases and methods of using modified Staphylococcus aureus Cas9 nucleases. Also provided herein are chimeric nucleases comprising an I-Tevl nuclease domain, and a Staphylococcus aureus Cas9 and methods of using the chimeric nuclease. Also provided herein are methods to edit genes by administering a chimeric nuclease to a cell or organism without the use of a viral vector.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: May 27, 2025
    Assignee: SPECIFIC BIOLOGICS INC.
    Inventors: David R. Edgell, Thomas A. McMurrough, Brent E. Stead, Odisho K. Israel
  • Patent number: 12297467
    Abstract: Methods to edit genes by administering a chimeric nuclease to a cell or organism without the use of a viral vector.
    Type: Grant
    Filed: June 22, 2022
    Date of Patent: May 13, 2025
    Assignee: SPECIFIC BIOLOGICS INC.
    Inventors: David R. Edgell, Thomas A. McMurrough, Brent E. Stead, Odisho K. Israel
  • Patent number: 11814658
    Abstract: Methods to edit genes by administering a chimeric nuclease to a cell or organism without the use of a viral vector.
    Type: Grant
    Filed: November 15, 2022
    Date of Patent: November 14, 2023
    Assignee: Specific Biologics Inc.
    Inventors: David R. Edgell, Thomas A. McMurrough, Brent E. Stead, Odisho K. Israel
  • Publication number: 20230322866
    Abstract: Phosphate-regulated expression of recombinant glycoprotein antigens and other recombinant proteins in diatoms is described herein. More specifically, described herein is the expression and purification of glycosylated, immunogenic, and serologically active receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, as well as SARS-CoV-2 nucleocapsid protein, in the marine pennate diatom Phaeodactylum tricornutum, as well as a functional lateral flow assay-based diagnostic device based on the produced recombinant RBD and nucleocapsid protein. Also described herein is the use of phosphate/iron levels in culture media to regulate expression/secretion of recombinant proteins under control of an HASP1 promoter in P. tricornutum or other suitable host cells. Also described herein is a method for increasing the expression/secretion of a recombinant protein by engineering the recombinant protein to lack a Tobacco Etch Virus (TEV) protease cleavage site.
    Type: Application
    Filed: August 30, 2022
    Publication date: October 12, 2023
    Inventors: Samuel S. Slattery, Daniel J. Giguere, Martin Flatley, Gregory B. Gloor, David R. Edgell
  • Publication number: 20230203464
    Abstract: Methods to edit genes by administering a chimeric nuclease to a cell or organism without the use of a viral vector.
    Type: Application
    Filed: November 15, 2022
    Publication date: June 29, 2023
    Inventors: David R. EDGELL, Thomas A. MCCMURROUGH, Brent E. STEAD, Odisho K. ISRAEL
  • Publication number: 20230016280
    Abstract: Methods to edit genes by administering a chimeric nuclease to a cell or organism without the use of a viral vector.
    Type: Application
    Filed: June 22, 2022
    Publication date: January 19, 2023
    Inventors: David R. EDGELL, Thomas A. MCCMURROUGH, Brent E. STEAD, Odisho K. ISRAEL
  • Publication number: 20220195404
    Abstract: Methods to edit genes by administering a chimeric nuclease to a cell or organism without the use of a viral vector.
    Type: Application
    Filed: October 29, 2021
    Publication date: June 23, 2022
    Inventors: David R. EDGELL, Thomas A. MCMURROUGH, Brent E. STEAD, Odisho K. ISRAEL
  • Publication number: 20220056457
    Abstract: A method for modulating a target organism in a microbiome, comprising contacting the microbiome with a cis-conjugative plasmid that can replicate and conjugate with organisms in the microbiome including the target organism, the conjugative plasmid comprising conjugation genes and a gene or a combination of genes capable of being expressed in the target organism and that only modulates the target organism in the microbiome. Also the isolated cis-conjugative plasmid comprising conjugation genes and a gene or a combination of genes capable of being expressed in a target bacteria within a microbiome or biofilm and that modulates the target bacteria in the microbiome or biofilm.
    Type: Application
    Filed: December 11, 2019
    Publication date: February 24, 2022
    Applicant: THE UNIVERSITY OF WESTERN ONTARIO
    Inventors: David R. EDGELL, Gregory B. GLOOR, Bogumil J. KARAS